Your browser doesn't support javascript.
loading
Nanomedicine: A Promising Way to Manage Alzheimer's Disease.
Khan, Nazeer Hussain; Mir, Maria; Ngowi, Ebenezeri Erasto; Zafar, Ujala; Khakwani, Muhammad Mahtab Aslam Khan; Khattak, Saadullah; Zhai, Yuan-Kun; Jiang, En-She; Zheng, Meng; Duan, Shao-Feng; Wei, Jian-She; Wu, Dong-Dong; Ji, Xin-Ying.
Affiliation
  • Khan NH; Henan International Joint Laboratory for Nuclear Protein Regulation, School of Basic Medical Sciences, Henan University, Kaifeng, China.
  • Mir M; Department of Pharmacy, Faculty of Biological Sciences, Quaid-i-Azam University, Islamabad, Pakistan.
  • Ngowi EE; Henan International Joint Laboratory for Nuclear Protein Regulation, School of Basic Medical Sciences, Henan University, Kaifeng, China.
  • Zafar U; Department of Biological Sciences, Faculty of Sciences, Dar es Salaam University College of Education, Dar es Salaam, Tanzania.
  • Khakwani MMAK; School of Natural Sciences, National University of Sciences and Technology, Islamabad, Pakistan.
  • Khattak S; Henan International Joint Laboratory for Nuclear Protein Regulation, School of Basic Medical Sciences, Henan University, Kaifeng, China.
  • Zhai YK; Henan International Joint Laboratory for Nuclear Protein Regulation, School of Basic Medical Sciences, Henan University, Kaifeng, China.
  • Jiang ES; Henan International Joint Laboratory for Nuclear Protein Regulation, School of Basic Medical Sciences, Henan University, Kaifeng, China.
  • Zheng M; School of Stomatology, Henan University, Kaifeng, China.
  • Duan SF; Henan International Joint Laboratory for Nuclear Protein Regulation, School of Basic Medical Sciences, Henan University, Kaifeng, China.
  • Wei JS; Institutes of Nursing and Health, School of Nursing and Health, Henan University, Kaifeng, China.
  • Wu DD; International Joint Center for Biomedical Innovation, School of Life Sciences, Henan University, Kaifeng, China.
  • Ji XY; Henan International Joint Laboratory for Nuclear Protein Regulation, School of Basic Medical Sciences, Henan University, Kaifeng, China.
Front Bioeng Biotechnol ; 9: 630055, 2021.
Article in En | MEDLINE | ID: mdl-33996777
Alzheimer's disease (AD) is a devastating disease of the aging population characterized by the progressive and slow brain decay due to the formation of extracellular plaques in the hippocampus. AD cells encompass tangles of twisted strands of aggregated microtubule binding proteins surrounded by plaques. Delivering corresponding drugs in the brain to deal with these clinical pathologies, we face a naturally built strong, protective barrier between circulating blood and brain cells called the blood-brain barrier (BBB). Nanomedicines provide state-of-the-art alternative approaches to overcome the challenges in drug transport across the BBB. The current review presents the advances in the roles of nanomedicines in both the diagnosis and treatment of AD. We intend to provide an overview of how nanotechnology has revolutionized the approaches used to manage AD and highlight the current key bottlenecks and future perspective in this field. Furthermore, the emerging nanomedicines for managing brain diseases like AD could promote the booming growth of research and their clinical availability.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Front Bioeng Biotechnol Year: 2021 Document type: Article Affiliation country: China Country of publication: Switzerland

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Front Bioeng Biotechnol Year: 2021 Document type: Article Affiliation country: China Country of publication: Switzerland